According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
Several other research analysts have also recently issued reports on the stock. Needham & Company LLC upped their target price on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the company a buy rating in a report on Tuesday, August 9th. Piper Jaffray Cos. restated an overweight rating and issued a $23.00 target price (up previously from $22.00) on shares of Amphastar Pharmaceuticals in a report on Wednesday, September 7th. BMO Capital Markets began coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, June 28th. They issued a market perform rating and a $17.00 target price for the company. Finally, Jefferies Group upped their target price on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a buy rating in a report on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Amphastar Pharmaceuticals has an average rating of Buy and an average target price of $20.00.
Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 18.425 on Monday. Amphastar Pharmaceuticals has a 12-month low of $10.50 and a 12-month high of $21.53. The firm has a 50-day moving average of $19.26 and a 200-day moving average of $16.18. The stock has a market cap of $831.35 million, a PE ratio of 59.821 and a beta of 1.83.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.23 EPS for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.22. Amphastar Pharmaceuticals had a net margin of 5.19% and a return on equity of 4.71%. The company had revenue of $68 million for the quarter, compared to the consensus estimate of $62.10 million. During the same period in the prior year, the firm posted ($0.09) EPS. The company’s quarterly revenue was up 26.4% compared to the same quarter last year. Equities analysts predict that Amphastar Pharmaceuticals will post $0.37 earnings per share for the current fiscal year.
In related news, President Jason B. Shandell sold 5,636 shares of the stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $18.01, for a total transaction of $101,504.36. Following the completion of the sale, the president now owns 208,948 shares in the company, valued at approximately $3,763,153.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Diane G. Gerst sold 24,046 shares of the stock in a transaction on Friday, August 19th. The stock was sold at an average price of $19.28, for a total transaction of $463,606.88. Following the sale, the executive vice president now owns 39,031 shares of the company’s stock, valued at approximately $752,517.68. The disclosure for this sale can be found here. Corporate insiders own 29.30% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Acrospire Investment Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 57.5% in the second quarter. Acrospire Investment Management LLC now owns 6,791 shares of the company’s stock worth $109,000 after buying an additional 2,479 shares in the last quarter. Atria Investments LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $190,000. C M Bidwell & Associates Ltd. acquired a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth $207,000. Simplex Trading LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $277,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Amphastar Pharmaceuticals during the first quarter worth $180,000. Hedge funds and other institutional investors own 35.87% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.